Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
43.09-1.03 (-2.33%)
At close: 04:03PM EDT
42.99 -0.10 (-0.23%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close44.12
Open43.76
Bid42.98 x 1000
Ask43.05 x 800
Day's Range43.08 - 43.78
52 Week Range40.94 - 61.71
Volume20,937,428
Avg. Volume17,806,612
Market Cap241.836B
Beta (5Y Monthly)0.64
PE Ratio (TTM)8.38
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.60 (3.63%)
Ex-Dividend DateNov 03, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
-3% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for PFE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Pfizer, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    18 days agoMorningstar
View more
  • Reuters

    German COVID vaccine developer BioNTech signs research deal with Australia

    BioNTech SE, the German biotech that developed a widely used COVID-19 vaccine with Pfizer Inc, will set up research and manufacturing centres in Australia based on the same technology, the company and Australian lawmakers said on Friday. The Nasdaq-listed company and Australia's Victoria state said they signed a partnership to create a centre, which would run clinical research of experimental messenger ribonucleic acid, or mRNA, vaccines and therapies with the aim of attracting experts from around the world. The partnership would also involve setting up mRNA manufacturing facilities in Melbourne, based on BioNTech's modular design, the company and the state government said.

  • Reuters

    UPDATE 1-Nearly 4 mln Americans received updated COVID boosters last week - CDC

    Around 3.9 million people in the United States received updated COVID-19 booster shots over the past week, the Centers for Disease Control and Prevention said on Thursday. The 11.5-million figure represents only 5.3% of the 215.5 million people in the United States aged 12 or older who are eligible to receive the shots because they have completed their primary vaccination series. The shots are being administered at a slower pace than last year, when the United States initially authorized COVID boosters just for older and immunocompromised people.

  • Reuters

    COVID rebound after Pfizer treatment likely due to robust immune response, study finds

    A rebound of COVID-19 symptoms in some patients after taking Pfizer's antiviral Paxlovid may be related to a robust immune response rather than a weak one, U.S. government researchers reported on Thursday. They concluded that taking a longer course of the drug - beyond the recommended five days - was not required to reduce the risk of a recurrence of symptoms as some have suggested, based on an intensive investigation of rebound in eight patients at the National Institutes of Health's Clinical Center. All patients in the study had developed robust immune responses, but researchers found higher levels of antibodies in the patients who experienced a rebound.

Advertisement
Advertisement